How certain cellular pathways interact with the virus that causes COVID-19
Function interactions between mitogen-activated protein kinases (MAPKs) and SARS-CoV-2
This study is looking at how the COVID-19 virus affects our cells and causes inflammation, with the hope of finding new treatments that could help people feel better and manage their symptoms.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11044092 on NIH RePORTER |
What this research studies
This research investigates how the SARS-CoV-2 virus affects human cells by activating specific cellular pathways known as mitogen-activated protein kinases (MAPKs). By using advanced technologies, the researchers aim to understand the role of these pathways in the severe inflammation seen in COVID-19 patients. The study employs various methods, including genetic screening and models of infection, to explore how inhibiting these pathways might reduce the virus's ability to replicate. The ultimate goal is to identify potential treatments that could help manage COVID-19 symptoms and improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research include adults who have been diagnosed with COVID-19 and are experiencing severe symptoms or complications.
Not a fit: Patients who have mild or asymptomatic COVID-19 may not receive significant benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for COVID-19 that target specific cellular pathways to reduce inflammation and viral replication.
How similar studies have performed: Other research has shown promise in targeting cellular pathways for treating viral infections, suggesting that this approach could be effective.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Johnson, Jeffrey R — Icahn School of Medicine at Mount Sinai
- Study coordinator: Johnson, Jeffrey R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.